Friday, July 10, 2026

Drug profile · INN

efmoroctocog alfa

efmoroctocog alfa (ELOCTA) is a coagulation factor viii exogenous protein.

EMA: approved Blood and blood forming organs (B02) B02BD02
Patents linked 0
Pipeline programs 2
News articles 0
Drug details — efmoroctocog alfa
Class
Blood and blood forming organs (B02)
Route
Patents
0
Programs
2
Data quality
0.83

Quick answer

efmoroctocog alfa (ELOCTA) is a coagulation factor viii exogenous protein.

Key facts

INN efmoroctocog alfa
Brand ELOCTA
Mechanism Coagulation factor VIII exogenous protein
Target Coagulation factor VIII
Therapeutic class Blood and blood forming organs (B02)
ATC code B02BD02

Mechanism of action

Coagulation factor VIII exogenous protein

Primary target: Coagulation factor VIII

Approval history

Authority Status Date
EMA approved

Pipeline programs

  1. WP45338 Phase 3 · HOFFMANN-LA ROCHE · Type 3 Von Willebrand Disease
  2. rFVIIIFc Approved · Sanofi Pasteur MSD · Hemophilia A With Inhibitors

Related & competitor drugs

  1. apixaban Blood and blood forming organs (B01)
  2. berotralstat Blood and blood forming organs (B06)
  3. bivalirudin Blood and blood forming organs (B01)
  4. c1 inhibitor (human) Blood and blood forming organs (B06)
  5. clopidogrel Blood and blood forming organs (B01)
  6. dabigatran etexilate Blood and blood forming organs (B01)

Frequently asked questions

What is efmoroctocog alfa?

efmoroctocog alfa (ELOCTA) is a coagulation factor viii exogenous protein.

What is the brand name for efmoroctocog alfa?

ELOCTA is a marketed brand name for efmoroctocog alfa. Check FDA Drugs@FDA for the current US label holder and prescribing information.